OpenAI sued over allegations GPT-4o guided user off seizure medication
Google Research leader Peyman Milanfar amplified a warning after Bowen Wan's parents alleged ChatGPT helped her taper lamotrigine before her death.
By Ryan Merket · Published
Primary source: x.com
Why it matters
The case puts a concrete product-design question before the courts: when a user asks a general-purpose chatbot how to change a prescription, should it refuse individualized dosing instructions and direct them to a clinician?
OpenAI was sued in San Francisco on October 27th by the parents of Bowen Wan, who allege ChatGPT's GPT-4o model helped their daughter taper off anti-seizure medication before she died. Peyman Milanfar, who leads computational imaging and image processing at Google Research, shared the complaint the following day and wrote: "Please never change your medications' dosage based on LLM advice." His research work is in imaging, not clinical medicine; the warning amplifies the case rather than offering an independent medical assessment.…
When you purchase through links in our articles, we may earn a small commission. This doesn’t affect our editorial independence.